Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated A/H7N9 Monovalent Subunit Influenza Virus Vaccine (H7N9c) in Adults 18 to <65 Years

Trial Profile

Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated A/H7N9 Monovalent Subunit Influenza Virus Vaccine (H7N9c) in Adults 18 to <65 Years

Completed
Phase of Trial: Phase I

Latest Information Update: 28 May 2015

At a glance

  • Drugs Influenza A virus H7N9 vaccines (Primary) ; MF 59
  • Indications Influenza A virus H7N9 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Novartis Vaccines
  • Most Recent Events

    • 01 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Nov 2013 Interim results were reported in a Novartis media release.
    • 11 Sep 2013 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top